ClinicalTrials.gg
CompletedNCT01782222BRIGHTUpdated Aug 31, 2018Results posted

Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy

A Phase 4 interventional study of Rotigotine and Placebo in Idiopathic Parkinson's Disease, sponsored by UCB BIOSCIENCES GmbH. Completed at 42 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-31.

Sponsored by UCB BIOSCIENCES GmbH (part of UCB S.A.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
22nd of 42
122 · median 123
Started
2013
with 1 other
Phase 4
8 of 44
none open now
Registered
34th of 44
by date
Lead sponsor
5 of 44
UCB BIOSCIENCES GmbH

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 22nd largest by enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2013, is one of 8 in phase 4, and was the 34th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

This trial is being conducted to assess the effects of Rotigotine over Placebo on improvement of Apathy and motor symptoms in subjects with early-stage and advanced stage idiopathic Parkinson´s Disease.

03

Conditions studied

  • Idiopathic Parkinson's Disease

Browse trials for

Keywords

  • Parkinson's Disease
  • Rotigotine
  • Apathy
  • Nonmotor
  • Motor
  • Neupro
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with early or advanced idiopathic Parkinson's Disease
  • Patients with advanced idiopathic Parkinson's Disease: intake of Levodopa on a stable dose of at least 200 mg/day
  • Unsatisfactory control of Parkinson's Disease motor symptoms under current treatment
  • Patients experiencing Apathy associated with Parkinson's Disease
  • Hoehn and Yahr stage score of I to IV
  • score ≥ 25
  • If an antidepressant drug is taken, the dose must be stable

Exclusion criteria

Exclusion Criteria:

  • Therapy with a Dopamine agonist
  • Discontinuation from pervious therapy with a dopamine agonist after an adequate length of treatment, at adequate dose, due to lack of efficacy
  • Any medical or psychiatric condition that jeopardizes / compromises patient's ability for participation
  • Patient has received Neuroleptics, Dopamine releasing substances, Dopamine modulating substances, Alpha-Methyldopa, Metoclopramide, MAO-A inhibitors, Budipine, or Tolcapone
  • Electroconvulsive therapy
  • Patient has a

    • current/anticipated psychotherapy or behavior therapy
    • history of deep brain stimulation
    • history of suicide attempt or has suicidal ideation
    • impulse control disorder
    • severe Depression
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    Rotigotine, high dose

    Rotigotine, transdermal patches, maximal 16 mg / 24 hours for patients with advanced Parkinson's Disease and 8 mg / 24 hours for those with early Parkinson's Disease

    Drug: Rotigotine

  • Experimental
    Rotigotine, low dose

    Rotigotine, transdermal patches, optimal dose, maximal 8 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours for those with early Parkinson's Disease

    Drug: Rotigotine

  • Placebo comparator
    Placebo

    Placebo transdermal patches

    Other: Placebo

Interventions

  • Rotigotine, transdermal patches: 10 cm\^2 (2 mg / 24 hours); 20 cm\^2 (4 mg / 24 hours); 30 cm\^2 (6 mg / 24 hours); 40 cm\^2 (8 mg / 24 hours) The maximum Rotigotine dose allowed is 8 mg / 24 hours or 16 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours or 8 mg / 24 hours for those with early Parkinson's Disease Duration: up to 21 weeks (including de-escalation)

    Also known as: (6S)-6-propyl-[2 (2 thienyl)ethyl]amino-5,6,7,8-tetrahydro-1-naphthalenol

  • OtherPlacebo

    Placebo, matching transdermal patches Duration: up to 21 weeks (including de-escalation)

06

What researchers measure

Primary outcomes

  1. Change From Baseline to the End of the Maintenance Period in the Score of the Apathy Evaluation Scale (AS) Rated by the Patient

    The Apathy Scale (AS) is an abbreviated version of the Apathy Evaluation Scale. The AS (Starkstein et al, 1992) consists of 14 items phrased as questions by the examiner that are to be answered on a 4-point Likert scale. It was developed specifically for subjects with Parkinson's disease because the Apathy Evaluation Scale was considered too demanding. The questions comprising the AS were answered by the subject. The total scores for Apathy Evaluation Scale ranges from 0 (best possible outcome) to 42 (worst possible outcome).

    Time frame: Baseline (Visit 2) until End of the Maintenance Period / Early Withdrawal (up to 19 weeks after Baseline)

  2. Change From Baseline to the End of the Maintenance Period in the Total Score of the Unified Parkinson's Disease Rating Scale (UPDRS) Parts II (Activities of Daily Living) + III (Motor Symptoms)

    Part II of the Unified Parkinson's Disease Rating Scale (UPDRS) assesses the subject's activities of daily living. Part III assesses motor function. The UPDRS is completed by questioning the subject about his/her general state in conjunction with any observations made by the investigator (or designee) since the previous visit. Part II is subject-rated and Part III is physician-rated. The UPDRS Part II (Activities of Daily Living) consists of 13 items scored between 0 and 4. The sum score was calculated as the sum of these 13 individual scores. The UPDRS Part III (motor subscale) consists of 27 items and sub items scored between 0 and 4. The sum score was calculated as sum of these 27 individual scores. The sum score of UPDRS Parts II and III is the sum of the corresponding single sum scores. A negative value indicates an improvement.

    Time frame: Baseline (Visit 2) until End of the Maintenance Period / Early Withdrawal (up to 19 weeks after Baseline)

Secondary outcomes

  1. Change From Baseline to the End of the Maintenance Period in the Score of the Apathy Evaluation Scale (AS) Rated by the Caregiver (Where Available)

    The Apathy Scale (AS) is an abbreviated version of the Apathy Evaluation Scale. The AS (Starkstein et al, 1992) consists of 14 items phrased as questions by the examiner that are to be answered on a 4-point Likert scale. It was developed specifically for subjects with Parkinson's disease because the Apathy Evaluation Scale was considered too demanding. The questions comprising the AS were answered by the caregiver. The questions were asked in a structured interview format. The caregiver was interviewed by appropriate medical staff and asked questions about the subject in the third person.The total scores for Apathy Evaluation Scale ranges from 0 (best possible outcome) to 42 (worst possible outcome).

    Time frame: Baseline (Visit 2) until End of the Maintenance Period / Early Withdrawal (up to 19 weeks after Baseline)

  2. Change From Baseline to the End of the Maintenance Period in the Sum Score of the 8-item Parkinson's Disease Questionnaire (PDQ-8)

    The 8-Item Parkinson's Disease Questionnaire (PDQ-8) (Peto et al, 1998) is a self-administered questionnaire that provides a reliable measure of overall health status. The PDQ-8 collects 8 items with 5 categories each (0=never, 1=occasionally, 2=sometimes, 3=often, 4=always or cannot do at all). The total score was calculated by summing the scores of all applicable questions and convert the resulting sum to a summary index score between 0 and 100 by multiplying with 100/32. A negative value indicates an improvement.

    Time frame: Baseline (Visit 2) until End of the Maintenance Period / Early Withdrawal (up to 19 weeks after Baseline)

  3. Change From Baseline to the End of the Maintenance Period in the Sum Score of the Mood / Cognition Domain of the Nonmotor Symptom Assessment Scale (NMSS)

    Nonmotor performance was assessed via the Nonmotor Symptom Assessment Scale (NMSS), an accepted scale that has been validated in an international study (Naidu et al, 2006; Chaudhuri et al, 2007), at the Baseline Visit as well as at the end of the Maintenance Period. The severity and frequency of the subject's nonmotor symptoms were assessed by the investigator (or designee) in the following 9 domain categories: cardiovascular, including falls; sleep/fatigue; mood/cognition; perceptual problems/hallucinations; attention/memory; gastrointestinal tract; urinary; sexual function; and miscellaneous. Items are scored for severity (from 0 (none) to 3 (severe)) and frequency (from 1 (rarely) to 4 (very frequent )). The score was calculated as severity x frequency. The theoretical minimum is 0 (best possible outcome) and maximum total score is 360 points (worst possible outcome).

    Time frame: Baseline (Visit 2) until End of the Maintenance Period / Early Withdrawal (up to 19 weeks after Baseline)

  4. Change From Baseline to the End of the Maintenance Period in the Sum Score of the Snaith Hamilton Pleasure Scale (SHAPS)

    The Snaith Hamilton Pleasure Scale (SHAPS) (Snaith et al, 1995) is a self-report instrument developed for the assessment of hedonic capacity. The sum of the 14 items scores range from 0 to 14. A higher score represents more anhedonic symptoms.

    Time frame: Baseline (Visit 2) until End of the Maintenance Period / Early Withdrawal (up to 19 weeks after Baseline)

  5. Change From Baseline to the End of the Maintenance Period in the Sum Score of the Beck Depression Inventory Second Edition (BDI-II)

    The Beck Depression Inventory (BDI) is a self-report instrument to measure depression symptoms and severity (Beck et al, 1961). The BDI-II is a revised version of the scale in order to be more consistent with the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for depression (Beck et al, 1996). There are 21 items in the BDI-II, classified as cognitive-affective (Items 1-13) and somatic-performance (Items 14-21) subscales. The degree of severity is indicated on a 4-point scale; items are rated from 0 (not at all) to 3 (extreme form of each symptom). Scores of 0-13 indicate minimal depression, 14-19 indicate mild depression, 20-28 indicate moderate depression, and 29-63 indicate severe depression.

    Time frame: Baseline (Visit 2) until End of the Maintenance Period / Early Withdrawal (up to 19 weeks after Baseline)

  6. Change From Baseline to the End of the Maintenance Period in the Sum Score of the Unified Parkinson's Disease Rating Scale (UPDRS) Part III (Motor Subscale) in "on" State

    Part III of the Unified Parkinson's Disease Rating Scale (UPDRS) assesses motor function. The UPDRS is completed by questioning the subject about his/her general state in conjunction with any observations made by the investigator (or designee) since the previous visit. The UPDRS Part III (motor subscale) had to be measured in the "on" state and consisted of 27 items and sub items scored between 0 and 4. The sum score ranged between 0 and 108 and was calculated as sum of the 27 individual scores. If 1 or more items were missing and could not be substituted with a previous post-Baseline value, the sum score was also missing. A negative value indicates an improvement.

    Time frame: Baseline (Visit 2) until End of the Maintenance Period / Early Withdrawal (up to 19 weeks after Baseline)

  7. Change From Baseline to the End of the Maintenance Period in the Score of the Clinical Global Impression Scale (CGI) Item I (Severity of Illness)

    The Clinical Global Impression (CGI) scales (Guy and Bonato, 1970) were initially developed for a risk-benefit estimation within the treatment of mentally ill patients. The 4 global scales (severity of illness, change in severity from Baseline, therapeutic efficacy, and tolerability of treatment) are used as different measures of treatment outcome in different kinds of pharmacological studies. The CGI Item 1 (severity of illness) collected 1 answer out of 8 categories (0-'Not assessed', 1-'Normal, not at all ill', 2-'Borderline ill', 3-'Mildly ill', 4-'Moderately ill', 5-'Markedly ill', 6-'Severely ill', and 7-'Among the most extremely ill patients') at each assessment. The category 0-'Not assessed' was considered as missing and therefore used neither for calculation nor for display purposes.

    Time frame: Baseline (Visit 2) until End of the Maintenance Period/Early Withdrawal (up to 19 weeks after Baseline)

07

Results

Posted Jan 19, 2015

Participant flow

This study was planned to be conducted globally with 480 subjects (160 subjects per treatment group for the Full Analysis Set). Approx. 600 subjects were planned for enrollment in order to obtain 504 subjects for randomization. Subjects were randomized in a 1:1:1 ratio to either Rotigotine low dose, Rotigotine high dose or Placebo.

Participant flow — Overall Study
MilestonePlaceboRotigotine, Low DoseRotigotine, High Dose
Started404141
Completed323037
Not completed8114
Withdrew: Adverse event453
Withdrew: Lack of efficacy210
Withdrew: Protocol violation100
Withdrew: Withdrawal by subject141
Withdrew: Moved to other state010

Outcome measures

PrimaryChange From Baseline to the End of the Maintenance Period in the Score of the Apathy Evaluation Scale (AS) Rated by the Patient

The Apathy Scale (AS) is an abbreviated version of the Apathy Evaluation Scale. The AS (Starkstein et al, 1992) consists of 14 items phrased as questions by the examiner that are to be answered on a 4-point Likert scale. It was developed specifically for subjects with Parkinson's disease because the Apathy Evaluation Scale was considered too demanding. The questions comprising the AS were answered by the subject. The total scores for Apathy Evaluation Scale ranges from 0 (best possible outcome) to 42 (worst possible outcome).

Time frame:
Baseline (Visit 2) until End of the Maintenance Period / Early Withdrawal (up to 19 weeks after Baseline)
Reported as:
Mean · scores on a scale
Change From Baseline to the End of the Maintenance Period in the Score of the Apathy Evaluation Scale (AS) Rated by the Patient
scores on a scalePlaceboRotigotine, Low DoseRotigotine, High Dose
Change From Baseline to the End of the Maintenance Period in the Score of the Apathy Evaluation Scale (AS) Rated by the Patient-4.4 ± 4.9-4.6 ± 6.7-4.9 ± 5.9
Statistical analysis
  • Placebo vs Rotigotine, Low Dose · ANCOVA · p = 0.977 · Least square mean: 0.04 · 95% CI -2.42 to 2.50ANCOVA model for the change from Baseline to End of Maintenance containing treatment and disease stage as factors, and Baseline value as covariate.
  • Placebo vs Rotigotine, High Dose · ANCOVA · p = 0.859 · Least square mean: -0.22 · 95% CI -2.61 to 2.18ANCOVA model for the change from Baseline to End of Maintenance containing treatment and disease stage as factors, and Baseline value as covariate.
PrimaryChange From Baseline to the End of the Maintenance Period in the Total Score of the Unified Parkinson's Disease Rating Scale (UPDRS) Parts II (Activities of Daily Living) + III (Motor Symptoms)

Part II of the Unified Parkinson's Disease Rating Scale (UPDRS) assesses the subject's activities of daily living. Part III assesses motor function. The UPDRS is completed by questioning the subject about his/her general state in conjunction with any observations made by the investigator (or designee) since the previous visit. Part II is subject-rated and Part III is physician-rated. The UPDRS Part II (Activities of Daily Living) consists of 13 items scored between 0 and 4. The sum score was calculated as the sum of these 13 individual scores. The UPDRS Part III (motor subscale) consists of 27 items and sub items scored between 0 and 4. The sum score was calculated as sum of these 27 individual scores. The sum score of UPDRS Parts II and III is the sum of the corresponding single sum scores. A negative value indicates an improvement.

Time frame:
Baseline (Visit 2) until End of the Maintenance Period / Early Withdrawal (up to 19 weeks after Baseline)
Reported as:
Mean · scores on a scale
Change From Baseline to the End of the Maintenance Period in the Total Score of the Unified Parkinson's Disease Rating Scale (UPDRS) Parts II (Activities of Daily Living) + III (Motor Symptoms)
scores on a scalePlaceboRotigotine, Low DoseRotigotine, High Dose
Change From Baseline to the End of the Maintenance Period in the Total Score of the Unified Parkinson's Disease Rating Scale (UPDRS) Parts II (Activities of Daily Living) + III (Motor Symptoms)-4.8 ± 10.4-12.4 ± 14.0-10.7 ± 8.4
Statistical analysis
  • Placebo vs Rotigotine, Low Dose · ANCOVA · p = 0.005 · Least square mean: -7.29 · 95% CI -12.30 to -2.28ANCOVA model for the change from Baseline to End of Maintenance containing treatment and disease stage as factors, and Baseline value as covariate.
  • Placebo vs Rotigotine, High Dose · ANCOVA · p = 0.015 · Least square mean: -6.06 · 95% CI -10.90 to -1.21ANCOVA model for the change from Baseline to End of Maintenance containing treatment and disease stage as factors, and Baseline value as covariate.
SecondaryChange From Baseline to the End of the Maintenance Period in the Score of the Apathy Evaluation Scale (AS) Rated by the Caregiver (Where Available)

The Apathy Scale (AS) is an abbreviated version of the Apathy Evaluation Scale. The AS (Starkstein et al, 1992) consists of 14 items phrased as questions by the examiner that are to be answered on a 4-point Likert scale. It was developed specifically for subjects with Parkinson's disease because the Apathy Evaluation Scale was considered too demanding. The questions comprising the AS were answered by the caregiver. The questions were asked in a structured interview format. The caregiver was interviewed by appropriate medical staff and asked questions about the subject in the third person.The total scores for Apathy Evaluation Scale ranges from 0 (best possible outcome) to 42 (worst possible outcome).

Time frame:
Baseline (Visit 2) until End of the Maintenance Period / Early Withdrawal (up to 19 weeks after Baseline)
Reported as:
Mean · scores on a scale
Change From Baseline to the End of the Maintenance Period in the Score of the Apathy Evaluation Scale (AS) Rated by the Caregiver (Where Available)
scores on a scalePlaceboRotigotine, Low DoseRotigotine, High Dose
Change From Baseline to the End of the Maintenance Period in the Score of the Apathy Evaluation Scale (AS) Rated by the Caregiver (Where Available)-1.5 ± 7.0-4.8 ± 8.0-5.5 ± 6.1
Statistical analysis
  • Placebo vs Rotigotine, Low Dose · ANCOVA · p = 0.200 · Least square mean: -3.20 · 95% CI -8.17 to 1.76ANCOVA model for the change from Baseline to End of Maintenance containing treatment and disease stage as factors, and Baseline value as covariate.
  • Placebo vs Rotigotine, High Dose · ANCOVA · p = 0.239 · Least square mean: -3.04 · 95% CI -8.19 to 2.10ANCOVA model for the change from Baseline to End of Maintenance containing treatment and disease stage as factors, and Baseline value as covariate.
SecondaryChange From Baseline to the End of the Maintenance Period in the Sum Score of the 8-item Parkinson's Disease Questionnaire (PDQ-8)

The 8-Item Parkinson's Disease Questionnaire (PDQ-8) (Peto et al, 1998) is a self-administered questionnaire that provides a reliable measure of overall health status. The PDQ-8 collects 8 items with 5 categories each (0=never, 1=occasionally, 2=sometimes, 3=often, 4=always or cannot do at all). The total score was calculated by summing the scores of all applicable questions and convert the resulting sum to a summary index score between 0 and 100 by multiplying with 100/32. A negative value indicates an improvement.

Time frame:
Baseline (Visit 2) until End of the Maintenance Period / Early Withdrawal (up to 19 weeks after Baseline)
Reported as:
Mean · scores on a scale
Change From Baseline to the End of the Maintenance Period in the Sum Score of the 8-item Parkinson's Disease Questionnaire (PDQ-8)
scores on a scalePlaceboRotigotine, Low DoseRotigotine, High Dose
Change From Baseline to the End of the Maintenance Period in the Sum Score of the 8-item Parkinson's Disease Questionnaire (PDQ-8)-3.8 ± 14.0-5.1 ± 20.4-10.0 ± 15.0
Statistical analysis
  • Placebo vs Rotigotine, Low Dose · ANCOVA · p = 0.519 · Least square mean: -2.09 · 95% CI -8.48 to 4.31ANCOVA model for the change from Baseline to End of Maintenance containing treatment and disease stage as factors, and Baseline value as covariate.
  • Placebo vs Rotigotine, High Dose · ANCOVA · p = 0.111 · Least square mean: -5.06 · 95% CI -11.29 to 1.17ANCOVA model for the change from Baseline to End of Maintenance containing treatment and disease stage as factors, and Baseline value as covariate.
SecondaryChange From Baseline to the End of the Maintenance Period in the Sum Score of the Mood / Cognition Domain of the Nonmotor Symptom Assessment Scale (NMSS)

Nonmotor performance was assessed via the Nonmotor Symptom Assessment Scale (NMSS), an accepted scale that has been validated in an international study (Naidu et al, 2006; Chaudhuri et al, 2007), at the Baseline Visit as well as at the end of the Maintenance Period. The severity and frequency of the subject's nonmotor symptoms were assessed by the investigator (or designee) in the following 9 domain categories: cardiovascular, including falls; sleep/fatigue; mood/cognition; perceptual problems/hallucinations; attention/memory; gastrointestinal tract; urinary; sexual function; and miscellaneous. Items are scored for severity (from 0 (none) to 3 (severe)) and frequency (from 1 (rarely) to 4 (very frequent )). The score was calculated as severity x frequency. The theoretical minimum is 0 (best possible outcome) and maximum total score is 360 points (worst possible outcome).

Time frame:
Baseline (Visit 2) until End of the Maintenance Period / Early Withdrawal (up to 19 weeks after Baseline)
Reported as:
Mean · scores on a scale
Change From Baseline to the End of the Maintenance Period in the Sum Score of the Mood / Cognition Domain of the Nonmotor Symptom Assessment Scale (NMSS)
scores on a scalePlaceboRotigotine, Low DoseRotigotine, High Dose
Change From Baseline to the End of the Maintenance Period in the Sum Score of the Mood / Cognition Domain of the Nonmotor Symptom Assessment Scale (NMSS)-4.6 ± 7.9-9.8 ± 12.1-9.8 ± 10.7
Statistical analysis
  • Placebo vs Rotigotine, Low Dose · ANCOVA · p = 0.060 · Least square mean: -3.62 · 95% CI -7.39 to 0.15ANCOVA model for the change from Baseline to End of Treatment containing treatment and disease stage as factors, and Baseline value as covariate.
  • Placebo vs Rotigotine, High Dose · ANCOVA · p = 0.034 · Least square mean: -3.88 · 95% CI -7.46 to -0.30ANCOVA model for the change from Baseline to End of Treatment containing treatment and disease stage as factors, and Baseline value as covariate.
SecondaryChange From Baseline to the End of the Maintenance Period in the Sum Score of the Snaith Hamilton Pleasure Scale (SHAPS)

The Snaith Hamilton Pleasure Scale (SHAPS) (Snaith et al, 1995) is a self-report instrument developed for the assessment of hedonic capacity. The sum of the 14 items scores range from 0 to 14. A higher score represents more anhedonic symptoms.

Time frame:
Baseline (Visit 2) until End of the Maintenance Period / Early Withdrawal (up to 19 weeks after Baseline)
Reported as:
Mean · scores on a scale
Change From Baseline to the End of the Maintenance Period in the Sum Score of the Snaith Hamilton Pleasure Scale (SHAPS)
scores on a scalePlaceboRotigotine, Low DoseRotigotine, High Dose
Change From Baseline to the End of the Maintenance Period in the Sum Score of the Snaith Hamilton Pleasure Scale (SHAPS)-0.5 ± 2.5-1.3 ± 2.2-0.9 ± 2.8
Statistical analysis
  • Placebo vs Rotigotine, Low Dose · ANCOVA · p = 0.334 · Least square mean: -0.38 · 95% CI -1.16 to 0.40ANCOVA model for the change from Baseline to End of Maintenance containing treatment and disease stage as factors, and Baseline value as covariate.
  • Placebo vs Rotigotine, High Dose · ANCOVA · p = 0.968 · Least square mean: 0.02 · 95% CI -0.74 to 0.77ANCOVA model for the change from Baseline to End of Maintenance containing treatment and disease stage as factors, and Baseline value as covariate.
SecondaryChange From Baseline to the End of the Maintenance Period in the Sum Score of the Beck Depression Inventory Second Edition (BDI-II)

The Beck Depression Inventory (BDI) is a self-report instrument to measure depression symptoms and severity (Beck et al, 1961). The BDI-II is a revised version of the scale in order to be more consistent with the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for depression (Beck et al, 1996). There are 21 items in the BDI-II, classified as cognitive-affective (Items 1-13) and somatic-performance (Items 14-21) subscales. The degree of severity is indicated on a 4-point scale; items are rated from 0 (not at all) to 3 (extreme form of each symptom). Scores of 0-13 indicate minimal depression, 14-19 indicate mild depression, 20-28 indicate moderate depression, and 29-63 indicate severe depression.

Time frame:
Baseline (Visit 2) until End of the Maintenance Period / Early Withdrawal (up to 19 weeks after Baseline)
Reported as:
Mean · scores on a scale
Change From Baseline to the End of the Maintenance Period in the Sum Score of the Beck Depression Inventory Second Edition (BDI-II)
scores on a scalePlaceboRotigotine, Low DoseRotigotine, High Dose
Change From Baseline to the End of the Maintenance Period in the Sum Score of the Beck Depression Inventory Second Edition (BDI-II)-3.3 ± 7.0-2.9 ± 5.9-3.7 ± 5.3
Statistical analysis
  • Placebo vs Rotigotine, Low Dose · ANCOVA · p = 0.899 · Least square mean: 0.16 · 95% CI -2.34 to 2.66ANCOVA model for the change from Baseline to End of Maintenance containing treatment and disease stage as factors, and Baseline value as covariate.
  • Placebo vs Rotigotine, High Dose · ANCOVA · p = 0.785 · Least square mean: -0.33 · 95% CI -2.68 to 2.03ANCOVA model for the change from Baseline to End of Treatment containing treatment and disease stage as factors, and Baseline value as covariate.
SecondaryChange From Baseline to the End of the Maintenance Period in the Sum Score of the Unified Parkinson's Disease Rating Scale (UPDRS) Part III (Motor Subscale) in "on" State

Part III of the Unified Parkinson's Disease Rating Scale (UPDRS) assesses motor function. The UPDRS is completed by questioning the subject about his/her general state in conjunction with any observations made by the investigator (or designee) since the previous visit. The UPDRS Part III (motor subscale) had to be measured in the "on" state and consisted of 27 items and sub items scored between 0 and 4. The sum score ranged between 0 and 108 and was calculated as sum of the 27 individual scores. If 1 or more items were missing and could not be substituted with a previous post-Baseline value, the sum score was also missing. A negative value indicates an improvement.

Time frame:
Baseline (Visit 2) until End of the Maintenance Period / Early Withdrawal (up to 19 weeks after Baseline)
Reported as:
Mean · scores on a scale
Change From Baseline to the End of the Maintenance Period in the Sum Score of the Unified Parkinson's Disease Rating Scale (UPDRS) Part III (Motor Subscale) in "on" State
scores on a scalePlaceboRotigotine, Low DoseRotigotine, High Dose
Change From Baseline to the End of the Maintenance Period in the Sum Score of the Unified Parkinson's Disease Rating Scale (UPDRS) Part III (Motor Subscale) in "on" State-3.4 ± 8.2-8.9 ± 10.4-8.1 ± 7.3
Statistical analysis
  • Placebo vs Rotigotine, Low Dose · ANCOVA · p = 0.014 · Least square mean: -4.96 · 95% CI -8.91 to -1.01ANCOVA model for the change from Baseline to End of Maintenance containing treatment and disease stage as factors, and Baseline value as covariate.
  • Placebo vs Rotigotine, High Dose · ANCOVA · p = 0.013 · Least square mean: -4.83 · 95% CI -8.63 to -1.03ANCOVA model for the change from Baseline to End of Maintenance containing treatment and disease stage as factors, and Baseline value as covariate.
SecondaryChange From Baseline to the End of the Maintenance Period in the Score of the Clinical Global Impression Scale (CGI) Item I (Severity of Illness)

The Clinical Global Impression (CGI) scales (Guy and Bonato, 1970) were initially developed for a risk-benefit estimation within the treatment of mentally ill patients. The 4 global scales (severity of illness, change in severity from Baseline, therapeutic efficacy, and tolerability of treatment) are used as different measures of treatment outcome in different kinds of pharmacological studies. The CGI Item 1 (severity of illness) collected 1 answer out of 8 categories (0-'Not assessed', 1-'Normal, not at all ill', 2-'Borderline ill', 3-'Mildly ill', 4-'Moderately ill', 5-'Markedly ill', 6-'Severely ill', and 7-'Among the most extremely ill patients') at each assessment. The category 0-'Not assessed' was considered as missing and therefore used neither for calculation nor for display purposes.

Time frame:
Baseline (Visit 2) until End of the Maintenance Period/Early Withdrawal (up to 19 weeks after Baseline)
Reported as:
Number · participants
Change From Baseline to the End of the Maintenance Period in the Score of the Clinical Global Impression Scale (CGI) Item I (Severity of Illness)
participantsPlaceboRotigotine, Low DoseRotigotine, High Dose
Normal, not ill at all112
Borderline ill623
Mildly ill191621
Moderately ill91012
Markedly ill211
Severely ill110
Amongst the most extremely ill subjects000
Missing251

Adverse events

Collected over Treatment Emergent Adverse Events (TEAEs) were reported from Baseline up to the Safety Follow-up Visit (approximately during 19 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—4/40 (10%)18/40 (45%)
Rotigotine, Low Dose—2/41 (4.9%)17/41 (41.5%)
Rotigotine, High Dose—1/41 (2.4%)15/41 (36.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboRotigotine, Low DoseRotigotine, High Dose
Abdominal painGastrointestinal disorders1/400/410/41
SepsisInfections and infestations1/400/410/41
Cerebrovascular accidentNervous system disorders1/400/410/41
Transient ischaemic attackNervous system disorders1/400/410/41
Small intestinal obstructionGastrointestinal disorders0/401/410/41
IleusGastrointestinal disorders0/401/410/41
AbscessInfections and infestations0/401/410/41
Cerebral haematomaNervous system disorders0/400/411/41
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlaceboRotigotine, Low DoseRotigotine, High Dose
InsomniaPsychiatric disorders6/401/412/41
NauseaGastrointestinal disorders4/404/412/41
HeadacheNervous system disorders4/401/413/41
Application site pruritusGeneral disorders2/404/411/41
SomnolenceNervous system disorders3/402/414/41
DepressionPsychiatric disorders2/404/411/41
Suicidal ideationPsychiatric disorders3/401/411/41
ConstipationGastrointestinal disorders1/402/413/41
Dry mouthGastrointestinal disorders0/400/413/41
Oedema peripheralGeneral disorders1/402/413/41

Baseline characteristics

The Baseline Analysis Population refers to the Safety Set (SS). The SS included all randomized subjects who received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)PlaceboRotigotine, Low DoseRotigotine, High DoseTotal
Mean69.0 ± 11.768.1 ± 10.570.2 ± 8.069.1 ± 10.1
Age, Customized
Age, Customized(participants)PlaceboRotigotine, Low DoseRotigotine, High DoseTotal
>18 - < 65 years14171243
≥ 65 years26242979
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRotigotine, Low DoseRotigotine, High DoseTotal
Female18141446
Male22272776
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboRotigotine, Low DoseRotigotine, High DoseTotal
Black1214
White383940117
Other/mixed1001
Weight
Weight(kilograms)PlaceboRotigotine, Low DoseRotigotine, High DoseTotal
Mean79.59 ± 14.7377.34 ± 17.9378.96 ± 15.9678.62 ± 16.17
Height
Height(centimeters)PlaceboRotigotine, Low DoseRotigotine, High DoseTotal
Mean167.16 ± 10.34169.25 ± 10.76170.88 ± 10.94169.10 ± 10.70
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter)PlaceboRotigotine, Low DoseRotigotine, High DoseTotal
Mean28.53 ± 4.7926.86 ± 4.8926.90 ± 3.8627.42 ± 4.57
08

Study locations

42 sites
  • 4320
    Birmingham, Alabama, United States
  • 4309
    Oxnard, California, United States
  • 4306
    Ormond Beach, Florida, United States
  • 4311
    Palm Beach Gardens, Florida, United States
  • 4313
    Tampa, Florida, United States
  • 4314
    Decatur, Georgia, United States
  • 4318
    Chicago, Illinois, United States
  • 4316
    Winfield, Illinois, United States
  • 4322
    Des Moines, Iowa, United States
  • 4304
    Kansas City, Kansas, United States
  • 4326
    Springfield, Massachusetts, United States
  • 4330
    Ocean Springs, Mississippi, United States
  • 4302
    Las Vegas, Nevada, United States
  • 4303
    Commack, New York, United States
  • 4317
    New York, New York, United States
  • 4323
    New York, New York, United States
  • 4319
    Asheville, North Carolina, United States
  • 4325
    Charlotte, North Carolina, United States
  • 4329
    Akron, Ohio, United States
  • 4312
    Cincinnati, Ohio, United States
  • 4324
    Beaufort, South Carolina, United States
  • 4332
    Charleston, South Carolina, United States
  • 4305
    San Antonio, Texas, United States
  • 4307
    Salt Lake City, Utah, United States
  • 4333
    Virginia Beach, Virginia, United States
  • 3001
    Innsbruck, Austria
  • 3003
    Linz, Austria
  • 3301
    Budapest, Hungary
  • 3302
    Debrecen, Hungary
  • 3509
    Gdansk, Poland
  • 3506
    Gdynia, Poland
  • 3504
    Poznan, Poland
  • 3801
    Banska Bystrica, Slovakia
  • 3805
    Bratislava, Slovakia
  • 3806
    Krompachy, Slovakia
  • 3807
    Zilina, Slovakia
  • 3901
    Ljubljana, Slovenia
  • 4001
    Barcelona, Spain
  • 4006
    Barcelona, Spain
  • 4009
    Oviedo, Spain
  • 4005
    Sevilla, Spain
  • 4010
    Sevilla, Spain
09

References and documents

Publications

  • Hauser RA, Slawek J, Barone P, Dohin E, Surmann E, Asgharnejad M, Bauer L. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease. BMC Neurol. 2016 Jun 7;16:90. doi: 10.1186/s12883-016-0610-7. PubMed 27267880 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of Jan 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2013
First posted
Feb 1, 2013
Start
Feb 2013
Primary completionActual
Jan 2014
CompletionActual
Mar 2014
Results first posted
Jan 19, 2015
Last update
Aug 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01782222
Responsible party
Sponsor
First posted
Feb 1, 2013
Start date
Feb 2013
Primary completion
Jan 2014
Completion
Mar 2014
Results posted
Jan 19, 2015
Last update
Aug 31, 2018

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion